Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 63Terminated 13Unknown 6Withdrawn 2Recruiting 2Active not recruiting 2No longer available 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 11Myeloid 8Lymphoid 8Plasma cell 2Classical hematology 2CNS 2Thoracic 1Sarcoma 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Neoplasms, Plasma Cell 2Multiple Myeloma 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Congenital Abnormalities 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Dexamethasone 48Calcium Dobesilate 20Bortezomib 20Lenalidomide 19Melphalan 16daratumumab 11Cyclophosphamide 11pomalidomide 10elotuzumab 8carfilzomib 8dexamethasone acetate 7pembrolizumab 6ixazomib 6fludarabine phosphate 6dexamethasone 21-phosphate 6venetoclax 5selinexor 5fludarabine 5auricularum 5Filgrastim 5liposomal doxorubicin 4Thalidomide 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Magnetic Resonance Spectroscopy 4Whole-Body Irradiation 3Vorinostat 3Simvastatin 3Nivolumab 3Mycophenolic Acid 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Busulfan × Plasma cell × Clear all
NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00301912 2012-10-02

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

University of California, San Francisco

Phase 2 Withdrawn
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Anemia, Blast Crisis, Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡